ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 61

Resolution of Systemic Joint Inflammatory Processes and Regeneration of Existing Bone Damage upon TNF Blockade As Monitored By In Vivo Multimodal PET-CT Imaging in Progressed Experimental Arthritis

Silvia Hayer1, Markus Zeilinger2,3, Volker Weiss3,4, Markus Seibt5, Birgit Niederreiter1, Tetyana Shvets6, Monika Dumanic6, Florian Pichler6, Marcus Hacker6, Josef S. Smolen7, Kurt Redlich8 and Markus Mitterhauser6, 1Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Faulty of Engineering, University of Applied Sciences, Winer Neustadt, Austria, 3Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, 4Faculty of Engineering, University of Applied Sciences, Wiener Neustadt, Austria, 5Department Internal Medicine III, Division Rheumatology, Medical University of Vienna, Vienna, Austria, 6Medical University of Vienna, Vienna, Austria, 7Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 8Division of Rheumatology, Medical University of Vienna, Vienna, Austria

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Animal models, bone remodeling, Imaging, rheumatoid arthritis, synovitis and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Biology and Pathology of Bone and Joint Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

To use in vivo multimodal [18F]FDG (fluoro-D-glucose, tracer for inflammation) and [18F]Sodium Fluoride (bone tracer) positron emission tomography/computed tomography (PET-CT) imaging for the monitoring of systemic inflammatory and bone remodeling processes as well as colocalized bone destructions before and after TNF blockade in human tumor necrosis factor transgenic (hTNFtg) mice, an established mouse model of chronic inflammatory, erosive polyarthritis.

Methods:

8 week-old hTNFtg mice were treated with anti-TNF antibodies (Infliximab, i.p., 3x times per week, 10mg/kg body weight) for 4 weeks. Before and after the treatment period mice received [18F]FDG or [18F]Sodium Fluoride (~25MBq) static PET scans (45min post injection) followed by whole-body and high resolution leg CT scans (800kV, 500µA, 800ms, 360 projections) using an Inveon PET/CT/SPECT multimodality system (Siemens Medical Solutions). PET reconstructions were conducted with OSEM3D/MAP, FBP algorithm. Standard uptake values (SUV) were calculated using PMOD software. Radiographic damage score was evaluated by in vivo CTs using InveonResearchWorkplace software. Joints were further analyzed by ex vivo µCT scans (Scanco µCT35) and H&E, TRAP and TB stained paraffin-sections.

Results: Before therapeutic intervention, we observed an increased accumulation of [18F]FDG in various joints of hTNFtg mice including knees, ankles and shoulders compared to wt littermates indicating ongoing systemic inflammatory processes. Moreover, existing bone destructions were detected by in vivoCTs. However, [18F]SodiumFluoride was equally accumulated within bone tissues such as long bones, in particular at growth plates, and vertebrae between both genotypes. After four weeks, placebo-treated hTNFtg animals showed significantly increased [18F]FDG SUVs as well as progressive bone destruction in knees, ankles and shoulders as shown by in vivoCTs. In contrast, TNF-blockade led to a significant decrease in [18F]FDG SUVs supposing complete resolution of inflammatory processes in those individuals. Comparison of repeated in vivoCT images demonstrated a significant reduction in radiographic bone damage score and reversal of existing bone destructions upon TNF blockade. Histological analysis demonstrated regeneration processes of former bone erosion sites present as refillings of cartilaginous or fibro-cartilaginous tissue as well as signs of endochondral ossifications or even intact bone surfaces upon TNF blockade. Surprisingly, we found no marked changes in [18F]Fluoride SUVs in joints between both hTNFtg groups and wt mice suggesting that age-related high [18F]Fluoride accumulations in growth plates interfere, thus preventing to monitor inflammatory bone damage.

Conclusion: In vivo small animal multimodal [18F]FDG, but not [18F]Fluoride, PET-CT imaging provides an objective, non-invasive imaging tool for the longitudinal monitoring of (I) reversibility of ongoing inflammatory processes in various joints and (II) regeneration of existing bone erosions during therapeutic intervention in TNF-driven experimental arthritis.


Disclosure: S. Hayer, None; M. Zeilinger, None; V. Weiss, None; M. Seibt, None; B. Niederreiter, None; T. Shvets, None; M. Dumanic, None; F. Pichler, None; M. Hacker, None; J. S. Smolen, AbbVie, Amgen, Astra-Zeneca, Astro, BMS, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO, Janssen, Eli Lilly and Company, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi-Aventis, UCB, 5,AbbVie, Janssen, Eli Lilly and Company, MSD, Pfizer, Roche, 2,AbbVie, Amgen, Astra-Zeneca, Astro, BMS, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO, Janssen, Eli Lilly and Company, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi-Aventis, UCB, 8; K. Redlich, None; M. Mitterhauser, None.

To cite this abstract in AMA style:

Hayer S, Zeilinger M, Weiss V, Seibt M, Niederreiter B, Shvets T, Dumanic M, Pichler F, Hacker M, Smolen JS, Redlich K, Mitterhauser M. Resolution of Systemic Joint Inflammatory Processes and Regeneration of Existing Bone Damage upon TNF Blockade As Monitored By In Vivo Multimodal PET-CT Imaging in Progressed Experimental Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/resolution-of-systemic-joint-inflammatory-processes-and-regeneration-of-existing-bone-damage-upon-tnf-blockade-as-monitored-by-in-vivo-multimodal-pet-ct-imaging-in-progressed-experimental-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resolution-of-systemic-joint-inflammatory-processes-and-regeneration-of-existing-bone-damage-upon-tnf-blockade-as-monitored-by-in-vivo-multimodal-pet-ct-imaging-in-progressed-experimental-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology